Vertex Pharmaceuticals INC / MA

At a glance

Vertex Pharmaceuticals INC / MA reported 2025 revenue of $12B, up 8.9% from $11.02B in 2024. Over 4 years since 2021 ($7.57B), that is growth of about 12.2% a year. Operating margin was 34.8%, down from 36.7% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2024.

In the last 12 months 13 insiders reported 0 open-market purchases and 52 sales ($158.1M). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a sale of $32.3M by Executive Chairman Jeffrey M Leiden on Nov 17, 2025.

Vertex Pharmaceuticals INC / MA filed 10 current reports (Form 8-K) in the last 12 months, most often for officer or director change (4), results of operations (4), material agreement (1) and shareholder vote results (1). The latest officer or director change was reported on Oct 20, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.

3 of the 20 investors tracked here held Vertex Pharmaceuticals INC / MA at the last quarter end, worth $432.4M combined. It is the largest weight for Renaissance Technologies (0.2% of its portfolio), followed by National Pension Service (Korea) (0.2%). Added: National Pension Service (Korea). Reduced: Renaissance Technologies and Bridgewater Associates.

Annual results

Fiscal year ends Dec 31 · incorporated in MA

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.